

[Carboplatin](#)

Essential medicine status

Section:

[8. Immunomodulators and antineoplastics](#) [8.2. Antineoplastics and supportive medicines](#) [8.2.1. Cytotoxic medicines](#)

ATC codes: [L01XA02](#)

Indication

Malignant neoplasms of nasopharynx ICD11 code: [2C3B.Z](#)

INN

Carboplatin

Medicine type

Chemical agent

List type

Complementary

Formulations

Parenteral > General injections > IV: 50 mg per 5 mL ; 150 mg per 15 mL ; 450 mg per 45 mL ; 600 mg per 60 mL

EML status history

First added in 2009 ([TRS 958](#))

Changed in 2015 ([TRS 994](#))

Sex

All

Age

Adolescents and adults

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Tags

Cancer

Wikipedia

[Carboplatin](#)

[DrugBank](#)

[Carboplatin](#)

Summary of evidence and Expert Committee recommendations

Carboplatin was originally added to the complementary list of the EML in 2009 as a treatment of advanced ovarian cancer. In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, listing for carboplatin on the complementary list of the EML for use in treatment protocols for nasopharyngeal cancer was specifically endorsed. The relevant extract from TRS994 regarding the Expert Committee's consideration of treatment protocols for nasopharyngeal cancer is attached.